Muse cells have become one of the most discussed topics in regenerative medicine over the past few years, and one of the most frequently misrepresented. Prospective patients ask us about them regularly, usually after encountering a clinic or supplier presenting Muse cells as a next-generation upgrade to conventional stem cell therapy.

The underlying science is real. It comes from a respected academic group at a major Japanese university, it has been published in credible journals, and it has been replicated by investigators outside the original lab. The clinical picture is considerably more complicated, and the commercial picture is messier still.

This article walks through what Muse cells are, how they differ biologically from the mesenchymal stem cells used in most cell therapy protocols including our own, what the clinical trials actually found, what happened to the program that ran those trials, and what any of this means for a patient trying to make a decision today.

Part 1: What Muse cells are

Discovery

Muse stands for Multilineage-differentiating Stress-Enduring.

The cells were identified in 2010 by Professor Mari Dezawa and colleagues at Tohoku University Graduate School of Medicine in Sendai, Japan. The finding was published in the Proceedings of the National Academy of Sciences by Kuroda and colleagues, and it came out of an observation that would be easy to dismiss as an artifact.

Dezawa's group subjected human bone marrow mesenchymal cell cultures to prolonged, severe stress, including long trypsin incubation that should have destroyed the population. A small fraction survived. Those survivors did not behave like the cells around them. They formed clusters resembling embryonic stem cell colonies, and they stained positive for stage-specific embryonic antigen 3 (SSEA-3), a surface marker associated with pluripotency.

The name followed the behavior. These were cells that endured stress and could differentiate across multiple lineages.

Where they live

The critical point, and the one most often lost in marketing material, is that Muse cells are not a distinct tissue source. They are a subpopulation that already exists inside ordinary mesenchymal cell populations.

They have been documented in:

• Bone marrow, at roughly 0.01 to 0.03 percent of the mononuclear fraction. This is considered their reserve site.
• Peripheral blood, at roughly 0.01 to 0.2 percent of the mononuclear fraction, with the number rising in response to injury or illness.
• Connective tissue of essentially every organ.
• Extraembryonic tissue, including umbilical cord and amnion.
• Cultured MSC and fibroblast preparations, where they typically make up one to several percent of the total population.

That last point deserves emphasis. Any expanded mesenchymal stem cell product, including a cord-derived one, contains a Muse fraction. Isolating "Muse cells" means sorting an existing MSC population for SSEA-3 positive cells and concentrating them. It is an enrichment step, not the discovery of a different cell.

Interestingly, the proportion is not fixed. Work published in 2025 found that culturing MSCs under hypoxic conditions roughly doubled the Muse cell fraction, driven by HIF2-alpha, and increased expression of pluripotency genes. This suggests the Muse phenotype is at least partly a state that mesenchymal cells can be pushed into, rather than a wholly separate lineage.

Defining characteristics

Four properties distinguish Muse cells from the bulk MSC population.

1. Tri-germ-layer differentiation without tumor formation.

A single Muse cell can self-renew and produce cells representing all three germ layers: ectoderm, mesoderm, and endoderm. This is the property that earns them the "pluripotent-like" description. They express Nanog, Oct3/4, and Sox2, the classic pluripotency transcription factors, but at moderate levels rather than the high levels seen in embryonic or induced pluripotent stem cells.

Crucially, they have low telomerase activity and do not show the exponential proliferative behavior of ES or iPS cells. Their doubling time is around 1.3 days, comparable to a human fibroblast. In reported transplantation studies they have not formed teratomas. This is the central safety argument for Muse cells: they offer breadth of differentiation without the tumorigenic risk that has held back true pluripotent stem cells clinically.

By contrast, conventional non-Muse MSCs differentiate only into mesodermal lineages: bone, cartilage, and fat.

2. Injury homing through sphingosine-1-phosphate.

Damaged and dying tissue releases sphingosine-1-phosphate (S1P), which functions as a universal damage signal. Muse cells express the S1P receptor 2 (S1PR2), which lets them detect that signal from circulation.

This has a practical consequence for intravenous delivery. A well-known limitation of IV-administered MSCs is pulmonary entrapment, where a large share of infused cells lodge in the lung capillary bed shortly after infusion. The Muse literature argues that S1P-directed homing allows these cells to move past the lung and accumulate preferentially at the injury site. Whether the difference is as clean in humans as it appears in animal models is not fully established, but the mechanism itself is well described.

3. Phagocytosis-dependent differentiation.

This is the most distinctive and, frankly, the most interesting part of the biology.

Muse cells share several features with monocytes and macrophages. They are 10 to 15 micrometers across, have a bean-shaped or heart-shaped nucleus, sense S1P, and express phagocytosis receptors. Where a macrophage phagocytoses debris to clear it, a Muse cell appears to phagocytose apoptotic cell fragments and then use their contents as differentiation instructions.

Work published by Wakao and colleagues in 2022 described the mechanism: transcription factors from the engulfed cell fragments translocate into the Muse cell nucleus, bind promoter regions, and drive expression of lineage-specific markers matching the cell type that was consumed. This happens within roughly 15 hours to several days. Conventional cytokine-driven differentiation of the same cells into cardiomyocytes or neural lineages takes weeks to months.

Single-cell RNA sequencing showed the resulting cells closely matched authentic differentiated cells with few errors in lineage direction. Disrupting phagocytosis, either by silencing the phagocytic receptors or by annexin V treatment, blocked differentiation both in culture and in animals.

In a mouse focal stroke model, human Muse cells were observed phagocytosing recipient neural apoptotic fragments and subsequently expressing neuronal markers.

4. Immune tolerance without immunosuppression.

Across every registered CL2020 trial, HLA-mismatched allogeneic Muse cells were given without HLA matching and without immunosuppressant drugs. No rejection events attributable to the cells were reported.

The proposed mechanism includes HLA-G expression, the same molecule involved in maternal-fetal immune tolerance at the placenta. In animal work, allogeneic Muse cells survived in post-infarct heart tissue as cardiac cells for six months, and xenogeneic human Muse cells were incorporated into mouse epidermis as collagen-producing cells, both without immunosuppression.

MSCs are also considered immune privileged, largely through low MHC class I and absent MHC class II expression, which is why allogeneic MSC therapy is standard practice. The Muse claim is that the tolerance is more durable and permits long-term engraftment rather than the transient presence typical of MSCs.

Part 2: How Muse cells compare to mesenchymal stem cells

The honest comparison is narrower than the marketing suggests, but it is not nothing.

Mechanism of action

MSCs work primarily by signaling. An infused MSC does not need to survive long or become anything to produce a therapeutic effect. It secretes growth factors, cytokines, chemokines, and extracellular vesicles that reduce inflammation, shift immune activity toward a regulatory profile, suppress apoptosis in stressed host cells, recruit endogenous repair cells, and promote angiogenesis. Most infused MSCs are cleared within days. The effect comes from what they say, not what they become.

This is well characterized and it is the basis of our own protocol. It is also why MSC therapy is best understood as a systemic anti-inflammatory and immunomodulatory intervention rather than a tissue-rebuilding one.

Muse cells are proposed to add a second mechanism on top of the first. They retain the bystander effects that MSCs have, including anti-inflammatory, anti-apoptotic, and anti-fibrotic activity. On top of that, the Tohoku work describes direct cell replacement: homing to the injury, phagocytosing damaged cells, adopting their identity, and integrating into the tissue for extended periods.

If that holds up in humans at clinically meaningful scale, it is a genuinely different therapeutic category. Signaling can slow damage and improve the environment. Replacement can restore lost structure.

Side by side

Conventional MSCsMuse cellsIdentityBulk mesenchymal populationSSEA-3 positive subset, one to several percent of that populationDifferentiation rangeMesoderm only (bone, cartilage, fat)All three germ layersPluripotency markersNot expressedNanog, Oct3/4, Sox2 at moderate levelsTumorigenicityVery lowVery low, no teratoma formation reportedPrimary mechanismParacrine signalingParacrine signaling plus phagocytosis-dependent cell replacementPersistence after IVDays, substantial pulmonary entrapmentReported long-term engraftment, S1P-directed homing past the lungImmune statusImmune privileged, allogeneic use standardImmune privileged with HLA-G, allogeneic use without immunosuppressantsSurface markersCD73, CD90, CD105 positiveAlso CD29, CD90, CD105 positive, plus SSEA-3Clinical evidence baseThousands of registered trials across many indicationsRoughly seven registered trials, one randomized and controlledIsolationStandard culture expansionRequires SSEA-3 magnetic or flow sorting

The last two rows are where the practical difference lies. The Muse mechanism is more ambitious on paper. The MSC evidence base is vastly larger in practice.

Part 3: What actually happened in the clinical trials

Between roughly 2018 and 2024, a clinical-grade Muse cell product called CL2020 was tested in Japan across seven indications. It was manufactured by Life Science Institute, Inc., a company within the Mitsubishi Chemical Group, from bone marrow mesenchymal stem cells sorted for the SSEA-3 positive fraction by magnetic cell separation.

The standard dose across nearly every trial was 15 million cells (1.5 x 10^7) delivered intravenously in about 10 to 15 minutes. That dose was originally extrapolated from an unpublished mouse myocardial infarction dose-finding study, scaled to human body weight, and then reused across indications once safety had been established.

All trials were conducted under Japan's Act on Securing Quality, Efficacy, and Safety of Products Including Pharmaceuticals and Medical Devices, and the Ordinance on Good Clinical Practice of Regenerative Medical Products.

Acute myocardial infarction (first-in-human)

Patients with ST-elevation myocardial infarction received a single IV dose roughly four days after onset.

Left ventricular ejection fraction improved from about 40.7 percent to 52.0 percent at 12 weeks, with a reported p value below 0.001. Wall motion score index also improved. No adverse drug reactions were attributed to the cells, and no changes were seen in liver or kidney panels or in inflammatory cytokines including IL-1-beta, TNF-alpha, IL-6, and interferon gamma over the 12-week window.

This was an uncontrolled first-in-human study. Ejection fraction typically recovers to some degree after revascularization, so a single-arm improvement cannot be attributed to the cells with confidence. A randomized, double-blind, placebo-controlled multicenter follow-up was initiated.

Subacute ischemic stroke

This is the most important trial in the entire program, because it is the only randomized, double-blind, placebo-controlled study.

Thirty-five patients with a modified Rankin Scale score of 3 or higher were randomized to a single IV dose of CL2020 (n=25) or placebo (n=10), given 14 to 28 days after stroke onset, without immunosuppressants. Safety was assessed at week 12 and efficacy out to 52 weeks.

The key endpoint was response rate, defined as the percentage of patients reaching mRS of 2 or below at week 12. Results: 40.0 percent in the CL2020 group (95% CI 21.1 to 61.3) versus 10.0 percent in the placebo group (95% CI 0.3 to 44.5). The lower bound of the treated group's confidence interval exceeded the pre-specified 8.7 percent threshold drawn from registry data, which is how the trial declared success.

Fugl-Meyer motor scale scores for both upper and lower limb showed statistically significant between-group differences.

The safety picture requires care in reading. Ninety-six percent of the CL2020 group experienced adverse events, versus 100 percent of the placebo group, so the raw AE rate reflects a sick post-stroke population rather than the drug. Adverse reactions specifically, meaning events considered treatment-related, occurred in 28 percent of the CL2020 group versus 10 percent of placebo, and included one Grade 4 status epilepticus. One patient died of aspiration pneumonia 345 days after treatment, not considered related.

The authors concluded CL2020 is a possible effective treatment for subacute ischemic stroke. That is appropriately hedged language. Thirty-five patients is small, the trial was single-center, the primary efficacy comparison was against a historical registry threshold rather than a straightforward superiority test against the placebo arm, and multiple investigators had financial relationships with Life Science Institute.

Amyotrophic lateral sclerosis (phase 2)

Five patients received CL2020 intravenously once a month for six total doses in a single-center open-label design. Enrollment finished in April 2021 and the last patient completed in September 2022.

Treatment was well tolerated. Twenty-eight adverse events occurred across five patients over 12 months, most commonly headache (four) and fatigue (three), with no serious side effects attributed to treatment.

On efficacy, the rate of change in ALSFRS-R score trended upward over the 12 months post-treatment compared with the three months before treatment. It did not reach statistical significance. The authors explicitly called for a double-blinded study with more patients and longer follow-up.

Five patients with no control arm in a disease with variable progression rates cannot establish efficacy. The value of this trial is the safety data.

Cervical traumatic spinal cord injury

Ten patients with C4 to C7 injuries at modified Frankel B1 or B2 severity received a single IV dose of 15 million cells. Average age was 49.3 years.

Two serious adverse events occurred, both judged unrelated to treatment. ISNCSCI motor scores, activities of daily living, and quality of life scores all improved significantly relative to the day of administration.

The authors were direct about the limitation: there was no control arm, and spontaneous neurological recovery after acute spinal cord injury is expected. Their own conclusion called for future trials with a control group to establish definitive efficacy.

Neonatal hypoxic-ischemic encephalopathy (SHIELD trial)

Nine neonates with moderate to severe HIE who had received therapeutic hypothermia were enrolled in a single-center open-label dose-escalation study. Three received 1.5 million cells, six received 15 million, given between 5 and 14 days of age.

No significant changes in heart rate, blood pressure, or oxygen saturation occurred during or after administration. One neonate had a mild gamma-glutamyltransferase elevation that resolved without treatment. All patients survived, and 67 percent showed normal developmental quotients across all three domains of the Kyoto Scale of Psychological Development 2001.

Dystrophic epidermolysis bullosa (phase 1/2)

An open-label, non-randomized, single-arm study enrolled five adults aged 17 to 49 with 13 refractory or recurrent ulcers persisting more than four weeks. Each received a single infusion of 15 million cells and was followed for 52 weeks.

Adverse events were mild or self-limiting: Grade 3 stomach pain, Grade 2 acquired lacrimal stricture, and Grade 1 fever, gastroenteritis, upper respiratory infection, and paresthesia of the upper arms. Ulcer size decreased.

The authors listed their own limitations candidly: a single small-dose administration may have limited efficacy, the included ulcers tended to be small, three of five patients had dominant DEB which may have skewed results through scratching, and only one biopsy was performed.

COVID-19 acute respiratory distress syndrome

A trial in this indication was initiated as part of the program.

The pattern

Across the whole program, roughly seventy patients received CL2020 in registered trials. The safety signal is genuinely good and consistent. No tumor formation, no rejection despite HLA mismatch and no immunosuppression, and no pattern of serious treatment-related events.

The efficacy signal is another matter. Six of the seven trials were open-label with no control arm, in conditions where spontaneous recovery is common. The one controlled trial had 35 patients and used a historical registry threshold as its efficacy benchmark. That is a foundation for further development, not a demonstration that the therapy works.

Part 4: What happened to the program

In February 2023, Mitsubishi discontinued development of CL2020.

The stated rationale, as reported at the time, referred to comprehensive consideration of the latest clinical developments, timelines for commercialization, and the product's pharmaceutical value.

Several things follow from this that are worth stating plainly.

The trial publications continued after the decision. The ALS phase 2 results appeared in Cell Transplantation in November 2023. The stroke RCT was published in December 2023. The spinal cord injury and SHIELD papers came out in 2024. Anyone reading the literature chronologically would reasonably conclude the program was accelerating. It had already been shut down.

A discontinuation is not a safety finding. Nothing in the public record indicates the program ended because of a safety problem, and the published safety data does not suggest one. Pharmaceutical companies terminate programs for commercial reasons constantly: cost of the pivotal trials required, projected market size, competing internal priorities, reimbursement uncertainty.

But it is also not nothing. The organization with the deepest access to the full data set, including unpublished results, looked at the clinical developments and the path to commercialization and decided not to fund the confirmatory trials. Those trials are exactly what the field needed. A sponsor that believed a pivotal readout was likely to succeed and likely to be commercially valuable would generally run it.

We would caution against reading too much into the decision in either direction. Some parties in the commercial Muse space have characterized Mitsubishi's rationale in ways that go beyond what the primary sources actually say, framing it as purely a business restructuring unrelated to the science. The published statement is broader than that and includes reference to clinical developments. The honest position is that the decision is ambiguous and the confirmatory evidence does not exist.

Part 5: The commercial landscape, and why it needs care

Since the Mitsubishi withdrawal, a number of commercial entities have begun marketing Muse cell products, licensing arrangements, or "authentic" Muse branding. Some are established clinics adding a service line. At least one is an intellectual property licensing company founded well after the original science, positioning itself as the gatekeeper of legitimate Muse cell manufacturing.

If you are evaluating any of these, three questions cut through most of the noise.

Whose evidence is being cited?

The CL2020 trial data belongs to a specific product, made by a specific manufacturer, through a specific process, under a program that no longer exists. Evidence generated with CL2020 does not transfer to a different company's cells produced by a different method, any more than one manufacturer's biosimilar inherits another's trial data. When a vendor's evidence page is populated with Niizuma 2023, Yamashita 2023, Sato 2024, and Koda 2024, those are CL2020 papers. They are not that vendor's results.

Watch for the distinction between preclinical citations, published clinical trials of someone else's product, and the vendor's own outcomes. Frequently the vendor's own evidence amounts to an uncontrolled observational registry or a single published case report.

Is the product actually SSEA-3 enriched?

Authentic Muse cell isolation requires sorting for SSEA-3 positive cells, typically by magnetic cell separation. This is a real manufacturing step with real cost. A product that has not undergone it is an MSC product containing the naturally occurring one to several percent Muse fraction, which is to say, a normal MSC product.

Ask for the sorting method and the percentage of SSEA-3 positive cells in the final product, with a certificate of analysis. A vendor who cannot produce this is not selling what they say they are selling.

What is being promised, and on what basis?

Muse cells have never been approved as a therapy in any jurisdiction. Every human being who has received a Muse cell product in a rigorous setting did so as a trial participant. Any commercial offering today is experimental. A vendor presenting it as an established treatment for a named condition is making a claim the literature does not support.

Part 6: Open scientific questions

Setting the commercial issues aside, several genuine scientific questions remain unresolved.

Does enrichment actually improve outcomes? Since MSC preparations already contain Muse cells, the therapeutic question is whether concentrating them produces better results than an unsorted product at equivalent or higher total cell dose. No head-to-head trial has answered this. It is a straightforward study to design and nobody has published it.

Does dose matter, and was CL2020 underdosed? Every CL2020 trial used 15 million cells, a figure extrapolated from a mouse cardiac study and then carried forward largely because it had already been shown safe. The epidermolysis bullosa authors specifically raised the possibility that a single administration of a relatively small number of cells limited efficacy. Whether higher doses or repeat dosing would change outcomes is unknown.

How much replacement actually occurs in humans? The cell replacement mechanism is well documented in rodent models with fluorescent tracking. Establishing the equivalent in living human patients is far harder, and the functional improvements reported in trials could plausibly be driven by the same paracrine effects MSCs produce, without meaningful engraftment.

Is Muse a fixed cell type or a state? The hypoxia finding, where the Muse fraction roughly doubled under low oxygen conditions with increased pluripotency gene expression, complicates the picture. If mesenchymal cells can be shifted into and out of the Muse phenotype by culture conditions, the boundary between "Muse" and "MSC" is less firm than a binary marker suggests.

Do source tissues differ? Most human trial work used bone marrow derived Muse cells. Muse cells from umbilical cord have been studied in animals, including a 2024 rat lung injury model using preterm and term cord derived cells that showed therapeutic effect without immunosuppressants. Whether cord-derived and marrow-derived Muse cells behave equivalently in humans is not established.

Part 7: Where DVC Stem stands

Our IRB-approved protocol, HPC/CTR/003, uses culture-expanded human umbilical cord tissue-derived mesenchymal stem cells sourced from Wharton's jelly, administered intravenously at 300 million cells per session. The tissue comes from ethically donated, full-term umbilical cords from AATB-certified United States suppliers, processed in an FDA-registered, cGMP-compliant, ISO 9001 and ISO 13485 certified laboratory. Our study is registered with the government of the Cayman Islands and subject to third-party IRB review on a 12-month cycle.

We do not offer Muse cell therapy, and here is our reasoning.

Umbilical cord tissue is one of the sources in which Muse cells naturally occur. Our product therefore contains a Muse fraction. We do not sort for it, we do not quantify it, and we do not make claims about it, because doing so would imply a therapeutic contribution we cannot demonstrate.

The evidence does not currently justify a switch. We would need to see a completed, adequately powered, randomized controlled trial showing that an enriched Muse product outperforms a conventional MSC product in a defined indication. That trial does not exist. The one randomized Muse trial ever completed enrolled 35 patients and compared against a registry threshold. The MSC evidence base, while itself imperfect and heavily weighted toward safety rather than definitive efficacy, is orders of magnitude larger.

We are not going to describe an experimental subpopulation as an available therapy. The distance between "promising mechanism with good early safety data" and "treatment you should pay for" is substantial, and we think patients are poorly served by clinics that collapse it.

If the picture changes, we will change with it. The Muse literature is genuinely interesting and we follow it closely. Dezawa's 2025 review in Biogerontology on the comparison between MSCs and Muse cells for healthspan optimization is worth reading for anyone who wants the primary-source version of the argument, and the 2025 Frontiers in Bioengineering and Biotechnology paper on the macrophage-like and pluripotent-like duality is the best current account of the mechanism.

But following the science and selling it are different activities, and we intend to keep them separate.

Common questions

Are Muse cells better than the mesenchymal stem cells DVC Stem uses?

Not on current evidence. They have a more ambitious proposed mechanism and a much thinner clinical record. They are also a subset of the same population, not a competing cell type.

Can I get Muse cell therapy anywhere legitimately?

Muse cells are not approved as a therapy anywhere. Some clinics offer Muse-branded products commercially. Those offerings are experimental regardless of how they are described, and their evidence base is generally borrowed from the discontinued CL2020 program rather than generated by the provider.

Did the trials fail?

No. The trials largely met their safety endpoints and several showed encouraging efficacy trends. What happened is that the sponsor stopped funding development before confirmatory trials could be run, which leaves the efficacy question open rather than answered negatively.

Does DVC Stem's product contain Muse cells?

Almost certainly yes, at the naturally occurring proportion found in cord-derived mesenchymal populations, typically one to several percent. We do not enrich for them or base any claims on them.

Will DVC Stem offer Muse cell therapy in future?

If controlled evidence establishes a benefit over conventional MSC therapy, we will evaluate it seriously. Until that evidence exists, no.

Selected references

Kuroda Y, Kitada M, Wakao S, et al. Unique multipotent cells in adult human mesenchymal cell populations. PNAS. 2010;107(19):8639-8643.

Kuroda Y, Wakao S, Kitada M, Murakami T, Nojima M, Dezawa M. Isolation, culture and evaluation of multilineage-differentiating stress-enduring (Muse) cells. Nature Protocols. 2013;8:1391-1415.

Wakao S, Oguma Y, Kushida Y, Kuroda Y, Tatsumi K, Dezawa M. Phagocytosing differentiated cell-fragments is a novel mechanism for controlling somatic stem cell differentiation within a short time frame. Cell Mol Life Sci. 2022;79(11):542.

Kuroda Y, Oguma Y, Hall K, Dezawa M. Endogenous reparative pluripotent Muse cells with a unique immune privilege system. Front Pharmacol. 2022;13:1027961.

Niizuma K, Osawa SI, Endo H, et al. Randomized placebo-controlled trial of CL2020, an allogenic Muse cell-based product, in subacute ischemic stroke. J Cereb Blood Flow Metab. 2023;43(12):2029-2039.

Yamashita T, Nakano Y, Sasaki R, et al. Safety and clinical effects of a Muse cell-based product in patients with amyotrophic lateral sclerosis: results of a phase 2 clinical trial. Cell Transplant. 2023.

Fujita Y, Nohara T, Takashima S, et al. Intravenous allogeneic multilineage-differentiating stress-enduring cells in adults with dystrophic epidermolysis bullosa: a phase 1/2 open-label study. J Eur Acad Dermatol Venereol. 2021;35(8):e528-e531.

Koda M, et al. Safety and feasibility of intravenous administration of a single dose of allogenic-Muse cells to treat human cervical traumatic spinal cord injury: a clinical trial. Stem Cell Res Ther. 2024;15:147.

Sato Y, et al. Safety and tolerability of a Muse cell-based product in neonatal hypoxic-ischemic encephalopathy with therapeutic hypothermia (SHIELD trial). Stem Cells Transl Med. 2024;13(11):1053.

Minatoguchi S, et al. Donor Muse cell treatment without HLA-matching tests and immunosuppressant treatment. Stem Cells Transl Med. 2024;13(6):532.

Dezawa M. Macrophage- and pluripotent-like reparative Muse cells are unique endogenous stem cells distinct from other somatic stem cells. Front Bioeng Biotechnol. 2025;13:1553382.

Dezawa M. Comparison of MSCs and Muse cells: the possible use for healthspan optimization. Biogerontology. 2025;26(4):139.

Prospective patients with questions about our protocol or the science behind it can speak with our team, and Dr. Cona is available for direct consultation before any treatment decision. Full protocol details are at dvcstem.com/protocol, and our curated peer-reviewed literature is at dvcstem.com/study-database.